{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:29:29Z","timestamp":1790713769113,"version":"4.1.0"},"reference-count":48,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Michael J. Fox Foundation","award":["MJFF13558"],"award-info":[{"award-number":["MJFF13558"]}]},{"name":"NIH HD","award":["R21 HD102788"],"award-info":[{"award-number":["R21 HD102788"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Substrate reduction therapy (SRT) in clinic adequately manages the visceral manifestations in Gaucher disease (GD) but has no direct effect on brain disease. To understand the molecular basis of SRT in GD treatment, we evaluated the efficacy and underlying mechanism of SRT in an immortalized neuronal cell line derived from a Gba knockout (Gba-\/-) mouse model. Gba-\/- neurons accumulated substrates, glucosylceramide, and glucosylsphingosine. Reduced cell proliferation was associated with altered lysosomes and autophagy, decreased mitochondrial function, and activation of the mTORC1 pathway. Treatment of the Gba-\/- neurons with venglustat analogue GZ452, a central nervous system-accessible SRT, normalized glucosylceramide levels in these neurons and their isolated mitochondria. Enlarged lysosomes were reduced in the treated Gba-\/- neurons, accompanied by decreased autophagic vacuoles. GZ452 treatment improved mitochondrial membrane potential and oxygen consumption rate. Furthermore, GZ452 diminished hyperactivity of selected proteins in the mTORC1 pathway and improved cell proliferation of Gba-\/- neurons. These findings reinforce the detrimental effects of substrate accumulation on mitochondria, autophagy, and mTOR in neurons. A novel rescuing mechanism of SRT was revealed on the function of mitochondrial and autophagy\u2013lysosomal pathways in GD. These results point to mitochondria and the mTORC1 complex as potential therapeutic targets for treatment of GD.<\/jats:p>","DOI":"10.3390\/cells10092286","type":"journal-article","created":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T10:02:11Z","timestamp":1630576931000},"page":"2286","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Substrate Reduction Therapy Reverses Mitochondrial, mTOR, and Autophagy Alterations in a Cell Model of Gaucher Disease"],"prefix":"10.3390","volume":"10","author":[{"given":"Yanyan","family":"Peng","sequence":"first","affiliation":[{"name":"Division of Human Genetics, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH 45229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Liou","sequence":"additional","affiliation":[{"name":"Division of Human Genetics, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH 45229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8209-1185","authenticated-orcid":false,"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Human Genetics, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH 45229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venette","family":"Fannin","sequence":"additional","affiliation":[{"name":"Division of Human Genetics, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH 45229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wujuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Clinical Mass Spectrometry Laboratory, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH 45229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo A.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth D. R.","family":"Setchell","sequence":"additional","affiliation":[{"name":"Department of Pathology, Clinical Mass Spectrometry Laboratory, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH 45229, USA"},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Grabowski","sequence":"additional","affiliation":[{"name":"Division of Human Genetics, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH 45229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Sun","sequence":"additional","affiliation":[{"name":"Division of Human Genetics, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH 45229, USA"},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,2]]},"reference":[{"key":"ref_1","unstructured":"Valle, D., Beaudet, A., Vogelstein, B., Kinzler, K.W., Antonarakis, S.E., and Ballabio, A. (2010). Gaucher disease. The Online Metabolic and Molecular Bases of Inherited Diseases, The McGraw-Hill Companies, Inc."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1002\/ajh.24063","article-title":"Gaucher disease types 1 and 3: Phenotypic characterization of large populations from the ICGG Gaucher Registry","volume":"90","author":"Grabowski","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ymgme.2020.12.291","article-title":"Gaucher disease: Basic and translational science needs for more complete therapy and management","volume":"132","author":"Grabowski","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bcmd.2006.11.003","article-title":"Gaucher disease among Chinese patients: Review on genotype\/phenotype correlation from 29 patients and identification of novel and rare alleles","volume":"38","author":"Choy","year":"2007","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1086\/302925","article-title":"Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease","volume":"66","author":"Koprivica","year":"2000","journal-title":"Am. J. Hum. Genet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/jhg.2015.27","article-title":"Novel mutations in the glucocerebrosidase gene of Indian patients with Gaucher disease","volume":"60","author":"Ankleshwaria","year":"2015","journal-title":"J. Hum. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/ajmg.a.20117","article-title":"Perinatal-lethal Gaucher disease","volume":"120A","author":"Mignot","year":"2003","journal-title":"Am. J. Med. Genet. A."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ymgme.2014.08.011","article-title":"CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11 years of therapy: Clinical, histopathologic, and biochemical findings","volume":"114","author":"Burrow","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF00690463","article-title":"Neuropathology of the Norrbottnian type of Gaucher disease. Morphological and biochemical studies","volume":"65","author":"Conradi","year":"1984","journal-title":"Acta. Neuropathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1194\/jlr.R003996","article-title":"Multi-system disorders of glycosphingolipid and ganglioside metabolism","volume":"51","author":"Xu","year":"2010","journal-title":"J. Lipid Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"648","DOI":"10.4161\/auto.6.5.12047","article-title":"Impaired autophagosomes and lysosomes in neuronopathic Gaucher disease","volume":"6","author":"Sun","year":"2010","journal-title":"Autophagy"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.4161\/auto.25878","article-title":"Defective quality control mechanisms and accumulation of damaged mitochondria link Gaucher and Parkinson diseases","volume":"9","author":"Osellame","year":"2013","journal-title":"Autophagy"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.cmet.2013.04.014","article-title":"Mitochondria and quality control defects in a mouse model of Gaucher disease--links to Parkinson\u2019s disease","volume":"17","author":"Osellame","year":"2013","journal-title":"Cell Metab."},{"key":"ref_15","first-page":"7031","article-title":"Neuronopathic Gaucher disease: Dysregulated mRNAs and miRNAs in brain pathogenesis and effects of pharmacologic chaperone treatment in a mouse model","volume":"24","author":"Dasgupta","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuint.2012.10.010","article-title":"Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage","volume":"62","author":"Cleeter","year":"2013","journal-title":"Neurochem. Int."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1093\/hmg\/ddu105","article-title":"Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice","volume":"23","author":"Xu","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Brown, R.A., Voit, A., Srikanth, M.P., Thayer, J.A., Kingsbury, T.J., Jacobson, M.A., Lipinski, M.M., Feldman, R.A., and Awad, O. (2019). mTOR hyperactivity mediates lysosomal dysfunction in Gaucher\u2019s disease iPSC-neuronal cells. Dis. Models Mech., 12.","DOI":"10.1242\/dmm.038596"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/sctm.20-0386","article-title":"Elevated glucosylsphingosine in Gaucher disease induced pluripotent stem cell neurons deregulates lysosomal compartment through mammalian target of rapamycin complex 1","volume":"10","author":"Srikanth","year":"2021","journal-title":"Stem Cells Transl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF00731489","article-title":"Treatment of Gaucher disease with an enzyme inhibitor","volume":"13","author":"Radin","year":"1996","journal-title":"Glycoconj. J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1080\/14656566.2021.1902989","article-title":"Current and emerging pharmacotherapy for Gaucher disease in pediatric populations","volume":"10","author":"Sam","year":"2021","journal-title":"Expert Opin. Pharm."},{"key":"ref_22","first-page":"1019","article-title":"CNS-accessible inhibitor of glucosylceramide synthase for substrate reduction therapy of neuronopathic Gaucher disease","volume":"24","author":"Marshall","year":"2016","journal-title":"Molecular"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Cabrera-Salazar, M.A., Deriso, M., Bercury, S.D., Li, L., Lydon, J.T., Weber, W., Pande, N., Cromwell, M.A., Copeland, D., and Leonard, J. (2012). Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0043310"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/jnc.15136","article-title":"Substrate reduction therapy using Genz-667161 reduces levels of pathogenic components in a mouse model of neuronopathic forms of Gaucher disease","volume":"156","author":"Blumenreich","year":"2021","journal-title":"J. Neurochem."},{"key":"ref_25","first-page":"769","article-title":"A new glucocerebrosidase-deficient neuronal cell model provides a tool to probe pathophysiology and therapeutics for Gaucher disease","volume":"9","author":"Westbroek","year":"2016","journal-title":"Dis. Models Mech."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"17483","DOI":"10.1073\/pnas.0708086104","article-title":"Murine models of acute neuronopathic Gaucher disease","volume":"104","author":"Enquist","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"pdb-prot072793","DOI":"10.1101\/pdb.prot072793","article-title":"A rapid Western blotting protocol for the Xenopus oocyte. Cold Spring Harb Protoc","volume":"2013","author":"Marchant","year":"2013","journal-title":"Cold Spring Harbor Protoc."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ymgme.2008.01.013","article-title":"Dependence of reversibility and progression of mouse neuronopathic Gaucher disease on acid beta-glucosidase residual activity levels","volume":"94","author":"Xu","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Sun, Y., Zhang, W., Xu, Y.H., Quinn, B., Dasgupta, N., Liou, B., Setchell, K.D., and Grabowski, G.A. (2013). Substrate compositional variation with tissue\/region and Gba1 mutations in mouse models--implications for Gaucher disease. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0057560"},{"key":"ref_30","first-page":"5126","article-title":"Modulating ryanodine receptors with dantrolene attenuates neuronopathic phenotype in Gaucher disease mice","volume":"25","author":"Liou","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1749-6632.2005.tb00031.x","article-title":"Saposin C: Neuronal effect and CNS delivery by liposomes","volume":"1053","author":"Chu","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ab.2017.07.009","article-title":"Mitochondrial membrane potential","volume":"552","author":"Zorova","year":"2018","journal-title":"Anal. Biochem."},{"key":"ref_33","first-page":"405","article-title":"Cytometric assessment of mitochondria using fluorescent probes","volume":"79","author":"Ronot","year":"2011","journal-title":"Cytom. A."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/15548627.2015.1009779","article-title":"Defects in calcium homeostasis and mitochondria can be reversed in Pompe disease","volume":"11","author":"Lim","year":"2015","journal-title":"Autophagy"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/hmg\/ddm289","article-title":"A block of autophagy in lysosomal storage disorders","volume":"17","author":"Settembre","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/08977190701779101","article-title":"Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function","volume":"25","author":"Jastrzebski","year":"2007","journal-title":"Growth Factors (Chur Switz.)"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1080\/15548627.2016.1271514","article-title":"Multistep regulation of TFEB by MTORC1","volume":"13","author":"Konda","year":"2017","journal-title":"Autophagy"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/jnc.13731","article-title":"Mitochondrial dysfunction in Parkinson\u2019s disease","volume":"139","author":"Bose","year":"2016","journal-title":"J. Neurochem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00401-007-0299-1","article-title":"Mitochondrial alterations in dorsal root ganglion cells in sporadic amyotrophic lateral sclerosis","volume":"114","author":"Sasaki","year":"2007","journal-title":"Acta. Neuropathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3389\/fnins.2018.00342","article-title":"Mitochondrial Quality Control in Neurodegenerative Diseases: Focus on Parkinson\u2019s Disease and Huntington\u2019s Disease","volume":"12","author":"Vila","year":"2018","journal-title":"Front. Neurosci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1124\/jpet.112.192138","article-title":"Mitochondrial dysfunction in neurodegenerative diseases","volume":"342","author":"Johri","year":"2012","journal-title":"J. Pharm. Exp."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1093\/hmg\/ddz184","article-title":"Intravenous infusion of iPSC-derived neural precursor cells increases acid beta-glucosidase function in the brain and lessens the neuronopathic phenotype in a mouse model of Gaucher disease","volume":"28","author":"Peng","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1432-1033.1969.tb19633.x","article-title":"Estimation of membrane potential and pH difference across the cristae membrane of rat liver mitochondria","volume":"7","author":"Mitchell","year":"1969","journal-title":"Eur J. Biochem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.tcb.2019.02.004","article-title":"Regulation and Function of Mitochondria-Lysosome Membrane Contact Sites in Cellular Homeostasis","volume":"29","author":"Wong","year":"2019","journal-title":"Trends Cell Biol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Ivanova, M.M., Changsila, E., Iaonou, C., and Goker-Alpan, O. (2019). Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0210617"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"103166","DOI":"10.1016\/j.ebiom.2020.103166","article-title":"Impaired autophagy: The collateral damage of lysosomal storage disorders","volume":"63","author":"Myerowitz","year":"2021","journal-title":"EBioMedicine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/jnc.14564","article-title":"Lysosome biogenesis in health and disease","volume":"148","author":"Bajaj","year":"2019","journal-title":"J. Neurochem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1093\/hmg\/ddv297","article-title":"Altered TFEB-mediated lysosomal biogenesis in Gaucher disease iPSC-derived neuronal cells","volume":"24","author":"Awad","year":"2015","journal-title":"Hum. Mol. Genet."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/9\/2286\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:54:43Z","timestamp":1760165683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/9\/2286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,2]]},"references-count":48,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["cells10092286"],"URL":"https:\/\/doi.org\/10.3390\/cells10092286","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,2]]}}}